早幼粒细胞胞外染色质加剧急性早幼粒细胞白血病的凝血与纤溶
急性早幼粒细胞白血病(APL)经全反式维甲酸(ATRA)治疗后早期出血死亡仍常见,机制不明。研究显示早幼粒细胞胞外染色质可增加凝血酶和纤溶酶生成、缩短血浆凝血时间、增加纤维蛋白形成,DNase I而非抗组织因子抗体可抑制这些效应;胞外染色质对内皮细胞有细胞毒性并促其转为促凝表型,DNase I阻断20%、活化蛋白C阻断31%。
要点
- 早幼粒细胞胞外染色质增加凝血酶和纤溶酶生成,缩短APL细胞血浆凝血时间并增加纤维蛋白形成。
- DNase I可抑制上述促凝效应,抗组织因子抗体不能抑制。
- 胞外染色质对 endothelial cells 有细胞毒性并促其转为促凝表型,DNase I阻断20%、活化蛋白C阻断31%。
核心结论
- 早幼粒细胞胞外染色质在APL凝血病中发挥致病作用。
- ATRA给药后高危APL患者残余的凝血紊乱可能通过加速胞外染色质降解来抑制内源性通路而得到治疗。
研究设计与样本
- 研究采用一系列凝血试验、免疫荧光染色和共孵育试验,评估早幼粒细胞胞外染色质与纤维蛋白及内皮细胞的相互作用。
主要发现
- 早幼粒细胞胞外染色质增加凝血酶和纤溶酶生成,缩短APL细胞血浆凝血时间,并增加纤维蛋白形成。
- DNase I可抑制上述效应,而抗组织因子抗体不能抑制。
- 免疫荧光染色显示早幼粒细胞胞外染色质和APL细胞上的磷脂酰丝氨酸为纤维蛋白沉积提供平台,并使血凝块更抗纤溶。
- 共孵育试验显示早幼粒细胞胞外染色质对内皮细胞有细胞毒性,使其转为促凝表型;DNase I阻断该细胞毒性20%,活化蛋白C阻断31%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite routine treatment of unselected acute promyelocytic leukemia (APL) with all-trans-retinoic acid (ATRA), early death because of hemorrhage remains unacceptably common, and the mechanism underlying this complication remains elusive. We have recently demonstrated that APL cells undergo a novel cell death program, termed ETosis, which involves release of extracellular chromatin. However, the role of promyelocytic extracellular chromatin in APL-associated coagulation remains unclear. Our objectives were to identify the novel role of ATRA-promoted extracellular chromatin in inducing a hypercoagulable and hyperfibrinolytic state in APL and to evaluate its interaction with fibrin and endothelial cells (ECs). Results from a series of coagulation assays have shown that promyelocytic extracellular chromatin increases thrombin and plasmin generation, causes a shortening of plasma clotting time of APL cells, and increases fibrin formation. DNase I but not anti-tissue factor antibody could inhibit these effects. Immunofluorescence staining showed that promyelocytic extracellular chromatin and phosphatidylserine on APL cells provide platforms for fibrin deposition and render clots more resistant to fibrinolysis. Additionally, coincubation assays revealed that promyelocytic extracellular chromatin is cytotoxic to ECs, converting them to a procoagulant phenotype. This cytotoxity was blocked by DNase I by 20% or activated protein C by 31%. Our current results thus delineate the pathogenic role of promyelocytic extracellular chromatin in APL coagulopathy. Furthermore, the remaining coagulation disturbance in high-risk APL patients after ATRA administration may be treatable by intrinsic pathway inhibition via accelerating extracellular chromatin degradation.
引用
- Cao M, Li T, He Z, et al. Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia. Blood. 2017. PMID: 28053193. doi:10.1182/blood-2016-09-739334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。